NCT01512797View on ClinicalTrials.gov

Treatment of Diabetes After Gastric Bypass With Sitagliptin

NACompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Sitagliptin phosphate

100 mg/day orally

OTHER

Placebo

1 Placebo Pill per day

Trial Locations (1)

10032

New York Obesity Nutrition Research Center, Columbia University, New York

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Blandine Laferrere

OTHER

NCT01512797 - Treatment of Diabetes After Gastric Bypass With Sitagliptin | Biotech Hunter | Biotech Hunter